Acolyte Biomedica, a UK based specialist in fighting the MRSA superbug, has been sold to US technology company 3M by its venture backers Angle, Porton Capital, Dstl/Ploughshare Innovations and Partnerships UK.
Acolyte Biomedica helps hospitals control high-risk infections through improved screening and targeted treatment of methicillin-resistant Staphylococcus aureus (MRSA), the well publicised bacteria that is resistant to certain antibiotics and occurs most frequently in hospital patients who have weakened immune systems.
The business is a UK joint venture company spun out of the Defence Science and Technology Laboratory (Dstl), the Ministry of Defence’s main centre of science. It has secured £3.7m in venture capital funding since its founding in 2000 with start-up financing from the Dstl and Angle. The company has exclusive rights to medical applications of a rapid bacterial testing method developed over 10 years within Dstl. Its products are based on technology used for detecting biological warfare, originally developed by Ministry of Defence.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: